Neutralizing Anti-gH antibody of varicella-zoster virus modulates distribution of gH and Induces gene regulation, mimicking latency

Journal of Virology

Volumn 85, Issue 16, 2011, Pages 8172-8180

  Shiraki, Kimiyasu ^a   Daikoku, Tohru ^a   Takemoto, Masaya ^a   Yoshida, Yoshihiro ^a   Suzuki, Kazuhiro ^b   Akahori, Yasushi ^b   Okuno, Toshiomi ^c   Kurosawa, Yoshikazu ^b   Asano, Yoshizo ^d,e  

^a UNIVERSITY OF TOYAMA   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E; GLYCOPROTEIN H; GLYCOPROTEIN H MONOCLONAL ANTIBODY; HEPATITIS B SURFACE ANTIGEN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANTIGENIC MODULATION; ARTICLE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; ENDOPLASMIC RETICULUM; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; VARICELLA ZOSTER VIRUS; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS INFECTIVITY; VIRUS LATENCY; VIRUS PATHOGENESIS; VIRUS STRAIN;

HUMAN HERPESVIRUS 3;

EID: 79961199513     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00435-11     Document Type: Article

References (52)

1. Akahori, Y., et al. 2009. Characterization of neutralizing epitopes of varicellazoster virus glycoprotein H. J. Virol. 83:2020-2024.
2. Beers, S. A., et al. 2010. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 115:5191-5201.
3. Beum, P. V., D. A. Mack, A. W. Pawluczkowycz, M. A. Lindorfer, and R. P. Taylor. 2008. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J. Immunol. 181:8120-8132.
4. Cohrs, R. J., M. B. Barbour, R. Mahalingam, M. Wellish, and D. H. Gilden. 1995. Varicella-zoster virus (VZV) transcription during latency in human ganglia: prevalence of VZV gene 21 transcripts in latently infected human ganglia. J. Virol. 69:2674-2678.
5. Cohrs, R. J., and D. H. Gilden. 2007. Prevalence and abundance of latently transcribed varicella-zoster virus genes in human ganglia. J. Virol. 81:2950-2956.
6. Cohrs, R. J., D. H. Gilden, P. R. Kinchington, E. Grinfeld, and P. G. Kennedy. 2003. Varicella-zoster virus gene 66 transcription and translation in latently infected human Ganglia. J. Virol. 77:6660-6665.
7. Cohrs, R. J., et al. 2000. Analysis of individual human trigeminal ganglia for latent herpes simplex virus type 1 and varicella-zoster virus nucleic acids using real-time PCR. J. Virol. 74:11464-11471.
8. Daikoku, T., et al. 2005. Architecture of replication compartments formed during Epstein-Barr virus lytic replication. J. Virol. 79:3409-3418.
9. Fujinami, R. S., E. Norrby, and M. B. Oldstone. 1984. Antigenic modulation induced by monoclonal antibodies: antibodies to measles virus hemagglutinin alters expression of other viral polypeptides in infected cells. J. Immunol. 132:2618-2621.
10. Fujinami, R. S., and M. B. Oldstone. 1980. Alterations in expression of measles virus polypeptides by antibody: molecular events in antibody-induced antigenic modulation. J. Immunol. 125:78-85.
11. Fujinami, R. S., and M. B. Oldstone. 1979. Antiviral antibody reacting on the plasma membrane alters measles virus expression inside the cell. Nature 279:529-530.
12. Hama, Y., et al. 2010. Antibody to varicella-zoster virus immediate-early protein 62 augments allodynia in zoster via brain-derived neurotrophic factor. J. Virol. 84:1616-1624.
13. Imakita, M., K. Shiraki, C. Yutani, and H. Ishibashi-Ueda. 2000. Pneumonia caused by rhinovirus. Clin. Infect. Dis. 30:611-612.
14. Joseph, B. S., and M. B. Oldstone. 1975. Immunologic injury in measles virus infection. II. Suppression of immune injury through antigenic modulation. J. Exp. Med. 142:864-876.
15. Kamiyama, T., H. Sato, T. Takahara, S. Kageyama, and K. Shiraki. 2000. Novel immunogenicity of Oka varicella vaccine vector expressing hepatitis B surface antigen. J. Infect. Dis. 181:1158-1161.
16. Kennedy, P. G., E. Grinfeld, and J. E. Bell. 2000. Varicella-zoster virus gene expression in latently infected and explanted human ganglia. J. Virol. 74: 11893-11898.
17. Kennedy, P. G., E. Grinfeld, and J. W. Gow. 1999. Latent varicella-zoster virus in human dorsal root ganglia. Virology 258:451-454.
18. Kuramoto, T., et al. 2010. Novel anti-cytomegalovirus activity of immunosuppressant mizoribine and its synergism with ganciclovir. J. Pharmacol. Exp. Ther. 333:816-821.
19. Kurosaki, K., et al. 2004. Therapeutic basis of vidarabine on adenovirusinduced haemorrhagic cystitis. Antivir. Chem. Chemother. 15:281-285.
20. Lungu, O., C. A. Panagiotidis, P. W. Annunziato, A. A. Gershon, and S. J. Silverstein. 1998. Aberrant intracellular localization of Varicella-Zoster virus regulatory proteins during latency. Proc. Natl. Acad. Sci. U. S. A. 95: 7080-7085.
21. Mahalingam, R., et al. 1996. Expression of protein encoded by varicellazoster virus open reading frame 63 in latently infected human ganglionic neurons. Proc. Natl. Acad. Sci. U. S. A. 93:2122-2124.
22. Meier, J. L., R. P. Holman, K. D. Croen, J. E. Smialek, and S. E. Straus. 1993. Varicella-zoster virus transcription in human trigeminal ganglia. Virology 193:193-200.
23. Okuda, T., et al. 2004. Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus. J. Med. Virol. 72:112-120.
24. Okuno, T., K. Yamanishi, K. Shiraki, and M. Takahashi. 1983. Synthesis and processing of glycoproteins of Varicella-zoster virus (VZV) as studied with monoclonal antibodies to VZV antigens. Virology 129:357-368.
25. Old, L. J., E. Stockert, E. A. Boyse, and J. H. Kim. 1968. Antigenic modulation. Loss of TL antigen from cells exposed to TL antibody. Study of the phenomenon in vitro. J. Exp. Med. 127:523-539.
26. Oldstone, M. B., R. M. Welsh, and B. S. Joseph. 1975. Pathogenic mechanisms of tissue injury in persistent viral infections. Ann. N. Y. Acad. Sci. 256:65-72.
27. Ono, Y., et al. 1983. The complete nucleotide sequences of the cloned hepatitis B virus DNA; subtype adr and adw. Nucleic Acids Res. 11:1747-1757.
28. Oshima, K., et al. 2008. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes. J. Med. Virol. 80:1769-1775.
29. Perng, G. C., and C. Jones. 2010. Towards an understanding of the herpes simplex virus type 1 latency-reactivation cycle. Interdisc. Perspect. Infect. Dis. 2010:262415.
30. Pulczynski, S. 1994. Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human malignant B cells. Leuk. Lymphoma. 15:243-252.
31. Pulczynski, S., A. M. Boesen, and O. M. Jensen. 1994. Modulation and intracellular transport of CD20 and CD21 antigens induced by B1 and B2 monoclonal antibodies in RAJI and JOK-1 cells-an immunofluorescence and immunoelectron microscopy study. Leuk. Res. 18:541-552.
32. Shiraki, K., et al. 1991. Development of immunogenic recombinant Oka varicella vaccine expressing hepatitis B virus surface antigen. J. Gen. Virol. 72:1393-1399.
33. Shiraki, K., et al. 1992. Processing of hepatitis B virus surface antigen expressed by recombinant Oka varicella vaccine virus. J. Gen. Virol. 73: 1401-1407.
34. Shiraki, K., et al. 1992. Comparison of antiviral assay methods using cell-free and cell-associated varicella-zoster virus. Antiviral Res. 18:209-214.
35. Shiraki, K., and F. Rapp. 1986. Establishment of herpes simplex virus latency in vitro with cycloheximide. J. Gen. Virol. 67:2497-2500.
36. Shiraki, K., et al. 2001. Construction of Oka varicella vaccine expressing human immunodeficiency virus env antigen. J. Med. Virol. 64:89-95.
37. Shiraki, K., and M. Takahashi. 1982. Virus particles and glycoprotein excreted from cultured cells infected with varicella-zoster virus (VZV). J. Gen. Virol. 61:271-275.
38. Shiraki, K., Y. Yoshida, Y. Asano, K. Yamanishi, and M. Takahashi. 2003. Pathogenetic tropism of varicella-zoster virus to primary human hepatocytesand attenuating tropism of Oka varicella vaccine strain to neonatal dermal fibroblasts. J. Infect. Dis. 188:1875-1877.
39. Southgate, T. D., et al. 2010. CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells. PLoS One 5:e9982.
40. Stevens, J. G. 1990. Transcripts associated with herpes simplex virus latency. Adv. Exp. Med. Biol. 278:199-204.
41. Sugano, T., et al. 1991. A human monoclonal antibody against varicellazoster virus glycoprotein III. J. Gen. Virol. 72:2065-2073.
42. Suzuki, K., Y. Akahori, Y. Asano, Y. Kurosawa, and K. Shiraki. 2007. Isolation of therapeutic human monoclonal antibodies for varicella-zoster virus and the effect of light chains on the neutralizing activity. J. Med. Virol. 79:852-862.
43. Takemoto, M., T. Imasawa, K. Yamanishi, and Y. Mori. 2009. Role of dendritic cells infected with human herpesvirus 6 in virus transmission to CD4(+) T cells. Virology 385:294-302.
44. Takemoto, M., et al. 2005. Human herpesvirus 6 open reading frame U14 protein and cellular p53 interact with each other and are contained in the virion. J. Virol. 79:13037-13046.
45. Taylor, R. P., and M. A. Lindorfer. 2010. Antigenic modulation and rituximab resistance. Semin. Hematol. 47:124-132.
46. Toyama, N., and K. Shiraki. 2009. Epidemiology of herpes zoster and its relationship to varicella in Japan: A 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. J. Med. Virol. 81:2053-2058.
47. Vleck, S. E., et al. 2010. Anti-glycoprotein H antibody impairs the pathogenicity of varicella-zoster virus in skin xenografts in the SCID mouse model. J. Virol. 84:141-152.
48. Wakkach, A., et al. 1999. Establishment of a human thymic myoid cell line. Phenotypic and functional characteristics. Am. J. Pathol. 155:1229-1240.
49. Wigdahl, B. L., H. C. Isom, and F. Rapp. 1981. Repression and activation of the genome of herpes simplex viruses in human cells. Proc. Natl. Acad. Sci. U. S. A. 78:6522-6526.
50. Wigdahl, B. L., A. C. Scheck, E. De Clercq, and F. Rapp. 1982. High efficiency latency and activation of herpes simplex virus in human cells. Science 217:1145-1146.
51. Zerboni, L., et al. 2010. Expression of varicella-zoster virus immediate-early regulatory protein IE63 in neurons of latently infected human sensory ganglia. J. Virol. 84:3421-3430.
52. Zimring, J. C., C. M. Cadwell, and S. L. Spitalnik. 2009. Antigen loss from antibody-coated red blood cells. Transfus. Med. Rev. 23:189-204.